Peking Union Medical College Hospital: Neuroendocrine Tumors trials
The registry lists 15 Neuroendocrine Tumors studies with Peking Union Medical College Hospital as lead sponsor. 3 are open to participants now and 0 have results posted.
Early Phase 1 3Phase 1 4Phase 2 6No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETsNot yet recruitingNCT06344832
- Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine TumorsRecruitingNCT06056362Phase 1/2
- 18F-MFBG PET/CT in the Evaluation of Neural Crest TumorRecruitingNCT05069220Early Phase 1
- Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/BiopsyCompletedNCT05171517
- Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine NeoplasmStatus unknownNCT05113355Phase 2
- Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine CarcinomaStatus unknownNCT05076786Phase 2
- Impact of Peptides and Chelators on Somatostatin Receptor AntagonistsStatus unknownNCT04491851Phase 2
- Gallium-68 Labeled LM3 PET/CT in Neuroendocrine TumorsCompletedNCT04318561Phase 1/2
- 68Ga-DOTATATE PET/CT in Neuroendocrine TumorStatus unknownNCT04041882Early Phase 1
- Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin AnalogsStatus unknownNCT03812939
- Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT03478358Phase 1
- 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT03308682Phase 1
- Dual SSTR2 and Integrin αvβ3 Targeting PET/CT ImagingStatus unknownNCT02817945Early Phase 1
- Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic NeoplasmsCompletedNCT02125929Not applicable
- Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine TumorCompletedNCT01845675Phase 2